Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Kesimpta is such a drug, taken as an injection under the skin once a month. According to the MS Trust , it reduces the number of relapses by about two-thirds (70%). Safety, efficacy, and adherence ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

The information on the calendar is subject to change at any moment and without prior notification. Users should verify the data independently and exercise due diligence in their financial activities.